RMC-9805 + RMC-6236 + gemcitabine + nab-paclitaxel

This is an investigational **combination therapy** consisting of two *novel small molecule inhibitors* (RMC-9805 and RMC-6236, both RAS(ON) inhibitors targeting KRAS-mutant solid tumors) with the approved chemotherapies **gemcitabine** (a nucleoside analog targeting DNA synthesis) and **nab-paclitaxel** (an albumin-bound nanoparticle formulation of paclitaxel that disrupts microtubules). RMC-9805 is a selective oral inhibitor targeting **KRAS G12D(ON)**, and RMC-6236 is an oral small molecule inhibitor targeting a broader range of RAS(ON) active forms. This regimen aims to synergistically inhibit tumor growth through direct RAS pathway blockade and cytotoxic effects of chemotherapy. The primary indication is for advanced gastrointestinal malignancies, especially **KRAS G12D-mutant solid tumors** and pancreatic or colorectal cancers[1][3][5][7][9].

Other names

Abraxane (nab-paclitaxel)Gemzar (gemcitabine)